Found 9 clinical trials
Raltegravir and Atazanavir Replacing Current Suppressive Treatment Because of Side Effects in Current Treatment
Subjects with HIV who have viral suppression on current regimen but also have side effects/intolerance will change their current regimen to a combination of Raltegravir and Atazanavir and
- 8 views
- 07 Nov, 2020
- 1 location
HIV Antiretroviral Drugs and Metabolism
will be studied before and at the end of four weeks of taking ritonavir, lopinavir/ritonavir or atazanavir/ritonavir. Hypothesis 2: NNRTI drugs do not increase HDL by increasing apo AI
- 6 views
- 07 Nov, 2020
- 1 location
Study Evaluating Pharmacokinetics (PK) Safety and Efficacy of Cobicistat-boosted Atazanavir (ATV/co) or Cobicistat-boosted Darunavir (DRV/co) and Emtricitabine/Tenofovir Alafenamide (F/TAF) in HIV-1 Infected Virologically Suppressed Pediatric Participants
Cohort 1: The primary objectives are: To evaluate the steady-state pharmacokinetics (PK) of Atazanavir (ATV) and Darunavir (DRV) and confirm the dose of Cobicistat-boosted
- 236 views
- 21 Aug, 2021
- 41 locations
HIV-1 Infected Patients Phase II Trial Dual Combination Doravirine/Raltegravir Open Label
The objective of antiretroviral therapy (ART) is the maintenance of HIV viral suppression, the optimal condition to prevent disease progression, to optimize immune restoration, to prevent the development of viral resistance and to reduce viral transmission. Antiretroviral therapy has to be maintained long life over decades in the absence of …
- 0 views
- 12 Feb, 2021
- 1 location
Assess Therapeutic Efficacy and Emergence of HIV Drug Resistance Following Initiation of TLD
medication that contains a boosted protease inhibitor (PI) drug (such as Lopinavir or Atazanavir) (Group 2). People taking TLD and receiving medication for TB that includes the drug rifampicin (RIF
- 12 views
- 16 Aug, 2021
- 14 locations
Pharmacokinetics of Antiretroviral Agents in HIV-infected Pregnant Women.
Due to the potential for pregnancy-induced changes in the pharmacokinetics of medication, one cannot assume that the currently licensed doses of the medication to be tested under this protocol lead to adequate exposure in an HIV-infected pregnant woman. For the agents under study no or limited pharmacokinetic data during pregnancy …
- 156 views
- 19 Jul, 2021
- 25 locations
Antiretroviral Pregnancy Registry (APR): Multi-sponsor Registry to Detect Any Major Teratogenic Effect Involving Any of the Registry Drugs When Administered to Pregnant Women.
The purpose of the Antiretroviral Pregnancy Registry (Registry) is to detect any major teratogenic effect involving any of the Registry drugs when administered to pregnant women. Registration is voluntary and confidential with information obtained from the health care provider. A Registry-assigned identifier allows for follow-up capability. Information on subjects is …
- 66 views
- 11 Jul, 2021
- 1 location
A Long-term Follow-up of the HIV-NAT Cohort
With HIV/AIDS increasingly considered a chronic disease, 24-, or 48-week data from antiretroviral studies are no longer sufficient. Only with long-term follow-up and outcome data will shed some much-needed light on the answers of questions that have stumped us for several years. Data from a large observational cohort of patients …
- 2 views
- 25 Jan, 2021
- 1 location
Pharmacokinetics of Atazanavir in Special Populations
The lack of data relating to the DDI between ATV and RIF is a major limitation to the use of ATV in patients who require treatment for TB. The VirTUAL Workpackage 2 will explore the necessary dose escalation required to overcome this interaction in non-pregnant HIV-infected adults who are virologically …
- 0 views
- 23 Jan, 2021
- 4 locations